BioSpace News Archive

Bio-Techne Corporation announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022, at 11:15 a.m. EDT.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive clinical results from several studies evaluating Clover’s COVID-19 vaccine candidate, SCB-2019, including follow-up efficacy at five months following primary vaccination and immune responses after a booster dose.

Innate Pharma SA, announced that the Company will hold a conference call on Thursday, March 24, 2022 at 2 p.m. CET / 9 a.m. ET.

KKR, a leading global investment firm, announced the closing of its previously announced investment in Biosynth Carbosynth, an innovative life sciences reagents, custom synthesis and manufacturing services company, as well as Biosynth Carbosynth’s acquisition of vivitide, a global provider of custom peptides and antibodies for the life sciences and biotech industry.

MediciNova, Inc. announced that it has received a Notice of Allowance from the Korean Intellectual Property Office which covers MN-001 and MN-002 for the treatment of advanced nonalcoholic steatohepatitis.

Invitae, a leading medical genetics company, announced full access to its Personalized Cancer Monitoring platform to help detect minimal or molecular residual disease in patients with solid tumors.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present and participate in a panel discussion at the 3rd Annual STING & TLR-Targeting Therapies Summit taking place virtually from March 22-24, 2022.

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.

ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, announced its operational and financial results for the fiscal year ended December 31, 2021.

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets.